ProQR Therapeutics (PRQR) Free Cash Flow (2013 - 2026)

ProQR Therapeutics has reported Free Cash Flow for 14 years, with the latest figure at -$13.6 million in Q1 2026.

• Quarterly Free Cash Flow rose 22.03% year-over-year to -$13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.8 million (down 29.86% YoY) and the FY2025 annual result came in at -$64.7 million, down 49.61% from the prior year.
• Free Cash Flow grew to -$13.6 million in Q1 2026 per PRQR's latest filing, from -$19.4 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $48.0 million in Q1 2023 and troughed at -$23.2 million in Q1 2022.
• A 5-year average of -$10.3 million and a median of -$14.1 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow slumped 476.15% in 2022, then soared 306.32% in 2023.
• Over 5 years, Free Cash Flow stood at -$19.7 million in 2022, then surged by 68.73% to -$6.1 million in 2023, then slumped by 156.1% to -$15.7 million in 2024, then slipped by 23.27% to -$19.4 million in 2025, then increased by 29.83% to -$13.6 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$13.6 million, -$19.4 million, and -$14.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.